Literature DB >> 12394529

Augmentation of seizure induction in electroconvulsive therapy: a clinical reappraisal.

Catherine Datto1, Anil K Rai, Howard J Ilivicky, Stanley N Caroff.   

Abstract

OBJECTIVE: Missed or abortive seizures during electroconvulsive therapy (ECT) may preclude completion of an effective course of treatment in some cases. Seizure augmentation, using proconvulsant agents, has been used to overcome resistance to the induction and continuation of seizure activity. In this review, we analyze published clinical data on the effects and safety of seizure augmentation techniques.
METHOD: Clinical studies and case reports were obtained through a MEDLINE literature search from 1966 to 2001, cross-referencing ECT and proconvulsant agents. Article references were also scanned for relevant studies. RESULTS AND
CONCLUSIONS: Data from clinical trials indicate that augmentation facilitates seizure induction when maximal electrical stimuli fail. Anesthetic modifications, including hyperventilation and substitution with etomidate, ketamine, or other agents, often are successful in overcoming seizure resistance and compare favorably with the use of caffeine. In a few studies, augmentation enabled the use of lower stimulus intensities and fewer treatments without loss of efficacy, even in patients not resistant to seizure induction. However, effects of proconvulsants must be reconciled with increasing evidence of the importance of stimulus dosing relative to seizure threshold and other parameters, now considered key to the efficacy of ECT. Further investigations of pharmacologic augmentation could facilitate the administration of ECT and could provide further insights concerning parameters of seizure efficacy and the mechanism of action underlying convulsive therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394529     DOI: 10.1097/00124509-200209000-00002

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  8 in total

Review 1.  Combined butalbital/acetaminophen/caffeine overdose: case files of the Robert Wood Johnson Medical School Toxicology Service.

Authors:  Christopher Bryczkowski; Ann-Jeannette Geib
Journal:  J Med Toxicol       Date:  2012-12

2.  Adenosine and ATP link PCO2 to cortical excitability via pH.

Authors:  Chris G Dulla; Peter Dobelis; Tim Pearson; Bruno G Frenguelli; Kevin J Staley; Susan A Masino
Journal:  Neuron       Date:  2005-12-22       Impact factor: 17.173

3.  Electroconvulsive therapy can benefit from controlled hyperventilation using a laryngeal mask.

Authors:  Martina Haeck; Benjamin Gillmann; Hildegard Janouschek; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-28       Impact factor: 5.270

4.  Overlooking the obvious? Influence of electrolyte concentrations on seizure quality parameters in electroconvulsive therapy.

Authors:  Michael Belz; Isabel Methfessel; Miriam Spang; Matthias Besse; Thorsten Folsche; Caspar Stephani; David Zilles
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-07-17       Impact factor: 5.270

5.  Release of adenosine and ATP during ischemia and epilepsy.

Authors:  Nicholas Dale; Bruno G Frenguelli
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 6.  The integrative role of the sigh in psychology, physiology, pathology, and neurobiology.

Authors:  Jan-Marino Ramirez
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

7.  Position statement and guidelines on unmodified electroconvulsive therapy.

Authors:  Chittaranjan Andrade; N Shah; P Tharyan; M S Reddy; M Thirunavukarasu; R A Kallivayalil; R Nagpal; N K Bohra; A Sharma; E Mohandas
Journal:  Indian J Psychiatry       Date:  2012-04       Impact factor: 1.759

8.  Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.

Authors:  Su-Hyuk Chi; Hyun-Ghang Jeong; Suji Lee; So-Young Oh; Seung-Hyun Kim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.